GSK plc (NYSE:GSK) Shares Acquired by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC boosted its stake in GSK plc (NYSE:GSK) by 15.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,717 shares of the pharmaceutical company’s stock after acquiring an additional 1,595 shares during the period. Foundations Investment Advisors LLC’s holdings in GSK were worth $396,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Primecap Management Co. CA boosted its stake in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after acquiring an additional 342,365 shares during the period. Provident Trust Co. grew its holdings in shares of GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after purchasing an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GSK shares. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Six analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.8 %

GSK stock opened at $35.35 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a market cap of $73.27 billion, a PE ratio of 22.96, a PEG ratio of 1.31 and a beta of 0.63. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a fifty day simple moving average of $34.01 and a 200 day simple moving average of $37.73.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.